Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arbutus Biopharma Cp
(NQ:
ABUS
)
2.785
-0.055 (-1.94%)
Streaming Delayed Price
Updated: 12:22 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
116,372
Open
2.860
Bid (Size)
2.780 (37)
Ask (Size)
2.790 (11)
Prev. Close
2.840
Today's Range
2.780 - 2.865
52wk Range
1.690 - 3.290
Shares Outstanding
99,161,234
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
May 02, 2024
ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+7.53%
+7.53%
1 Month
-9.87%
-9.87%
3 Month
+12.75%
+12.75%
6 Month
+50.54%
+50.54%
1 Year
+6.70%
+6.70%
More News
Read More
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
April 05, 2024
Via
InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
April 04, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
April 04, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 04, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
April 03, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
October 05, 2023
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
September 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.